Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stan B Kaye

Showing results (11-20 of 77) with videos related to

Pageof 8
Sort By:
Nature Reviews. Clinical Oncology|April 14, 2010
Imaging ovarian cancer and peritoneal metastases--current and emerging techniquesStavroula Kyriazi, Stan B Kaye, Nandita M deSouza
Current Opinion in Oncology|May 21, 2010
PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancersCraig P Carden, Timothy A Yap, Stan B Kaye
Nature Reviews. Cancer|February 22, 2013
Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and researchEmma Kipps, David S P Tan, Stan B Kaye
British Journal of Cancer|March 30, 2016
PARP inhibitors: the race is onJessica S Brown, Stan B Kaye, Timothy A Yap
Nature Reviews. Cancer|February 25, 2009
Beyond chemotherapy: targeted therapies in ovarian cancerTimothy A Yap, Craig P Carden, Stan B Kaye
Nature Reviews. Clinical Oncology|August 5, 2010
Weekly paclitaxel in the treatment of recurrent ovarian cancerRichard D Baird, David S P Tan, Stan B Kaye
Advances in Experimental Medicine and Biology|June 13, 2008
Ovarian cancer: can we reverse drug resistance?David S P Tan, Joo Ern Ang, Stan B Kaye
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 2, 2012
Combining antiangiogenics to overcome resistance: rationale and clinical experienceVictor Moreno Garcia, Bristi Basu, L Rhoda Molife, et al.
Nature Reviews. Clinical Oncology|January 12, 2011
Emerging therapeutic targets in endometrial cancerKonstantin J Dedes, Daniel Wetterskog, Alan Ashworth, et al.
Cancer Biomarkers : Section a of Disease Markers|May 18, 2011
Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy: correlation of apparent diffusion coefficients with epithelial and stromal densities on histologyStavroula Kyriazi, Emma Nye, Gordon Stamp, et al.
Pageof 8

Showing results (11-20 of 77) with videos related to

Sort By:
Pageof 8
Nature Reviews. Clinical Oncology|April 14, 2010
Imaging ovarian cancer and peritoneal metastases--current and emerging techniquesStavroula Kyriazi, Stan B Kaye, Nandita M deSouza
Current Opinion in Oncology|May 21, 2010
PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancersCraig P Carden, Timothy A Yap, Stan B Kaye
Nature Reviews. Cancer|February 22, 2013
Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and researchEmma Kipps, David S P Tan, Stan B Kaye
British Journal of Cancer|March 30, 2016
PARP inhibitors: the race is onJessica S Brown, Stan B Kaye, Timothy A Yap
Nature Reviews. Cancer|February 25, 2009
Beyond chemotherapy: targeted therapies in ovarian cancerTimothy A Yap, Craig P Carden, Stan B Kaye
Nature Reviews. Clinical Oncology|August 5, 2010
Weekly paclitaxel in the treatment of recurrent ovarian cancerRichard D Baird, David S P Tan, Stan B Kaye
Advances in Experimental Medicine and Biology|June 13, 2008
Ovarian cancer: can we reverse drug resistance?David S P Tan, Joo Ern Ang, Stan B Kaye
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 2, 2012
Combining antiangiogenics to overcome resistance: rationale and clinical experienceVictor Moreno Garcia, Bristi Basu, L Rhoda Molife, et al.
Nature Reviews. Clinical Oncology|January 12, 2011
Emerging therapeutic targets in endometrial cancerKonstantin J Dedes, Daniel Wetterskog, Alan Ashworth, et al.
Cancer Biomarkers : Section a of Disease Markers|May 18, 2011
Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy: correlation of apparent diffusion coefficients with epithelial and stromal densities on histologyStavroula Kyriazi, Emma Nye, Gordon Stamp, et al.
Pageof 8